Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 922-925

  Zoufaly, A ^a,b   Jochum, J ^a   Hammerl, R ^c   Nassimi, N ^c   Raymond, Y ^d   Burchard, G D ^c   Schmiedel, S ^a   Drexler, J F ^e   Campbell, N K ^f   Taka, N ^d   Awasom, C ^d   Metzner, K J ^f   Van Lunzen, J ^a   Feldt, T ^c,g  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

^c BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^d Bamenda   (Cameroon)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Adherence; Africa; HIV drug resistance

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ADULT; AGED; ANTIRETROVIRUS THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CAMEROON; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NEXT GENERATION SEQUENCING; NONHUMAN; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; VIRAL LOAD TESTING; VIRUS LOAD; VIRUS MUTATION; COHORT ANALYSIS; DNA SEQUENCE; HIGH THROUGHPUT SEQUENCING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MIDDLE AGED; MISSENSE MUTATION; RURAL POPULATION; TREATMENT FAILURE; YOUNG ADULT;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAMEROON; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MUTATION, MISSENSE; PROSPECTIVE STUDIES; RURAL POPULATION; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; VIRAL LOAD; YOUNG ADULT;

EID: 84928201928     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku470     Document Type: Article

References (17)

1. Coetzee D, Hildebrand K, Boulle A et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-95.
2. Stringer JS, Zulu I, Levy J et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-93.
3. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4: e298.
4. Sigaloff KC, Hamers RL, Menke J et al. Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries. Clin Infect Dis 2012; 54 Suppl 4: S294-9.
5. Gupta RK, Jordan MR, Sultan BJ et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380:1250-8.
6. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. 2010. http://whqlibdoc. who.int/publications/2010/9789241599764_eng.pdf.
7. Di Giallonardo F, Zagordi O, Duport Y et al. Next-generation sequencing of HIV-1 RNA genomes: determination of error rates and minimizing artificial recombination. PLoS One 2013; 8: e74249.
8. Laurent C, Kouanfack C, Laborde-Balen G et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis 2011; 11:825-33.
9. Liegeois F, Vella C, Eymard-Duvernay S et al. Virological failure rates and HIV-1 drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon. J Int AIDS Soc 2012; 15:17985.
10. Bangsberg DR, Charlebois ED, Grant RM et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003; 17:1925-32.
11. El-Khatib Z, Katzenstein D, Marrone G et al. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One 2011; 6: e17518.
12. Luebbert J, Tweya H, Phiri S et al. Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in Lilongwe, Malawi. Clin Infect Dis 2012; 55:441-8.
13. Li JZ, Paredes R, Ribaudo HJ et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011; 305:1327-35.
14. Balduin M, Oette M, Daumer MP et al. Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naive patients and their impact on the virological failure. J Clin Virol 2009; 45:34-8.
15. Boltz VF, Bao Y, Lockman S et al. Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP. J Infect Dis 2014; 209:703-10.
16. Metzner KJ, Scherrer AU, Von Wyl V et al. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. AIDS 2014; 28:2231-9.
17. De Luca A, Hamers RL, Schapiro JM. Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries. J Infect Dis 2013; 207 Suppl 2: S63-9.